Perspective for use of the radionuclide drugs in the treatment of malignant tumors in Russiaw
https://doi.org/10.24411/2588-0519-2018-10044
Abstract
This article reviews perspective of the targeted radionuclide therapy (TRT) as one of the rapidly growing fields of nuclear medicine. The characteristics, features of action, advantages and disadvantages of the most used α- and β-emitters (223Ra, 213Bi, 225Ac, 211At, 89Sr, 90Y, 131I, 153Sm, 177Lu) are presented. New approaches based on the use of α-emitting isotopes in the treatment of castration-resistant prostate cancer with bone metastases, acute myeloid leukemia, melanoma, neuroendocrine tumors, and brain tumors are discussed. The importance of TRT in routine clinical practice is underlined. The use of targeted radionuclide therapy in clinical settings in our country should be expanded
About the Authors
S. K. Zyryanov
Peoples' Friendship University of Russia, Moscow
Russian Federation
Russian Federation
K. E. Zatolochina
City Clinical Hospital No. 24 of the Moscow City Health Department, Moscow
Russian Federation
Russian Federation
References
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. (2014). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359–386. DOI: 10.1002/ijc.29210. Epub 2014 Oct 9.
2. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment. AJR Am J Roentgenol. 2017 Aug;209(2):277–288. DOI: 10.2214/AJR.17.18264. Epub 2017 May 2.
3. Gill MR, Falzone N, Du Y, Vallis KA. Targeted radionuclide therapy in combined-modality regimens. Lancet Oncol. 2017 Jul;18(7):e414–e423. DOI: 10.1016/S1470-2045(17)30379-0.
4. Zukotynski K, Jadvar H, Capala J, Fahey F. Targeted radionuclide therapy: practical applications and future prospects. Biomark Cancer. 2016; 8(suppl):35–38.
5. Родионова А., Шубина Д. Атомный взрыд: чем объясняется плачев¬ное состояние российской ядерной медицины // Vademecum. 2018;3. [Rodionova A, SHubina D. Atomnyi vzryd: chem ob yasnyaetsya plachevnoe sostoyanie rossiiskoi yadernoi meditsiny / Vademecum. 2018;3. (In Russ.).] URL: https://vademec.ru/article/atomnyy_vzryd-_chem_obyasnyaetsya_plachevnoe_ sostoyanie_rossiyskoy_yadernoy_meditsiny/
6. Уйба В.В. Ядерная медицина - проект будущего. Федеральное медико- биологическое агентство. [Uiba VV. Yadernaya meditsina — proekt budushchego. Federal'noe mediko-biologicheskoe agentstvo. (In Russ.).] URL: http://ipheb.ru/netcat_files/userfiles/7_Uyba.pdf
7. Курашвили Ю. Стратегия развития радиофармацевтической про¬мышленности в РФ 2030. ГК Росатом. IV ежегодный международный форум по развитию фармацевтической отрасли в России. «ФармЭволюция». [Kurashvili Yu. Strategiya razvitiya radiofarmatsevticheskoi promyshlennosti v RF 2030. GK Rosatom. IV ezhegodnyi mezhdunarodnyi forum po razvitiyu farmatsevticheskoi otrasli v Rossii. "FarmEvolyutsiya". (In Russ).] URL: https:// events.vedomosti.ru/events/pharma18/materials
8. Руководство для врачей. / Под ред. А.Ф. Цыба, Ю.С. Мардынского. – М.: ООО «МК», 2010. – 552 с. [Rukovodstvo dlya vrachei. / Ed by AF Tsyba, YuS Mardynskogo. (In Russ.).]
9. Middendorp M, Grünwald F. Update on recent developments in the therapy of differentiated thyroid cancer. Semin Nucl Med. 2010 ;40 (2):145–152. Elsevier Inc.
10. Van Dodewaard-de Jong J, Oprea-Lager D, Hooft L, et al. Radiopharmaceuticals for palliation of bone pain in patients with castration-resistant prostate cancer metastatic to bone: a systematic review. Eur Urol. 2015. European Association of Urology.
11. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46(1):62S– 6S.
12. Valkema R, Pauwels S, Kvols L, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3] octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006;36(2):147–156.
13. De Jong M, Valkema R, Jamar F, et al. Somatostatin receptor targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002;32(2):133–140.
14. Koppe MJ, Postema EJ, Aarts F, et al. Antibody-guided radiation therapy of cancer. Cancer Metastasis Rev. 2005;24(4):539–567.
15. Ghobrial I, Witzig T. Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin’s Lymphoma. Oncology (Williston Park). 2004;18(3):623–630.
16. Chamarthy MR, Williams SC, Moadel RM. Radioimmunotherapy of non-Hodgkin’s lymphoma: from the "magic bullets" to “radioactive magic bullets. Yale J Biol Med. 2011;84(4):391–407.
17. Volkert WA, Goeckleler WF, Ehrhardt GJ, et al. Therapeutic radionuclides: production and decay property considerations. J Nucl Med. 1991;32(1):174–185.
18. Kassis AI. Therapeutic radionuclides: biophysical and radiobiologic principles. Semin Nucl Med. 2008 Sep;38(5):358–366. DOI: 10.1053/j.semnuclmed.2008.05.002.
19. Marcu L, Bezak E. Biomedical Physics in Radiotherapy for Cancer Ed. Allen B. 2012. Springer-Verlag London.
20. Dash A, Knapp FF, Pillai MR. Targeted radionuclide therapy--an overview. Curr Radiopharm. 2013 Sep;6(3):152–180.
21. Marcua L, Bezak E, Allend BJ. Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials. Critical Reviews in Oncology / Hematology. 123 (2018): 7–20.
22. Buchegger F, Perillo-Adamer F, Dupertuis YM, et al. Auger radiation targeted into DNA: a therapy perspective. Eur J Nucl Med Mol Imaging. 2006; 33(11):1352–1363.
23. Kassis AI. The amazing world of auger electrons. Int J Radiat Biol. 2004 Nov-Dec;80(11–12):789–803.
24. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted {alpha}- particle therapy. J Nucl Med. 2005 Jan;46 Suppl 1:199S–204S.
25. Kim YS, Brechbiel MW. An overview of targeted alpha therapy. Tumour Biol. 2012 Jun;33(3):573–590. DOI: 10.1007/s13277-011-0286-y. Epub 2011 Dec 6.
26. FDA Approves Xofigo for Advanced Prostate Cancer [Internet]. 2013. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=203971.
27. Dekempeneera Y, Keyaertsa M, Krasniqia A, et al. Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle. Expert opinion on biological therapy. 2016. Vol. 16, No. 8, 1035–1047. URL: http://dx.doi.org/10.1080/14712598.2016.1185412.
28. Harrison MR, Wong TZ, Armstrong AJ, George DJ. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res. 2013;5:1–14. DOI: 10.2147/CMAR.S25537. Epub 2013 Jan 8.
29. Parker C, Heinrich D, O’Sullivan JM, et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Oncol. 2012;30(Suppl 5) Abstr 8.
30. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–223. DOI: 10.1056/NEJMoa1213755. PMID: 23863050.
31. Parker C, Vogelzang NJ, Sartor O, et al. 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA. J Clin Oncol. 2015;33(suppl 7):abstr. 195. Proceedings of the Genitourinary Cancers Symposium.
32. Pais HL, Alho I, Vendrell Is, et al. Radionuclides in oncology clinical practice — review of the literature. Dalton Transactions. 2017;46:14475–14487. DOI: 10.1039/C7DT01929G
33. Gill MR, Falzone N, Du Y, Vallis KA. Targeted radionuclide therapy in combined-modality regimens. Lancet Oncol. 2017 Jul;18(7):e414–e423. DOI: 10.1016/S1470-2045(17)30379-0.
34. Allend B, Marcua L, Bezak E. Targeted Alpha Therapy for Cancer. 2016 In book: Advances in Medical Physics, Edition: Volume 6, Publisher: Medical Physics Publishing, Editors: Devon J. Godfrey, Jacob Van Dyk, Shiva K. Das, Bruce H. Curran, and Anthony B. Wolbarst, pp. 177–202.
35. Jurcic JG, Larson SM, Sgouros G, et al. Targeted α particle immunotherapy for myeloid leukemia. Blood. 2002;100:1233–1239.
36. Caron PC, Jurcic JC, Scott AM, et al. A phase 1B trial of humanized antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood. 1994 83:1760–1768.
37. Jurcic J, Divgi C, McDevitt M. Potential for myeloablation with yttrium- 90-Hu (anti-CD33) in myeloid leukemia. Proc. Am. Soc. Clin. Oncol. 2000;19(8):M195.
38. Schwartz MA, Lovett DR, Redner A, et al. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J. Clin. Oncol. 1993;11(2):294–303.
39. Jurcic J, Rosenblat T, McDevitt M. Phase I Trial of the Targeted Alpha- Particle Nano-Generator Actinium-225(225Ac)-Lintuzumab (anti-CD33; HuM195) In Acute Myeloid Leukemia (AML). Blood. 2011;118:768.
40. Jurcic JG, Rosenblat TL. Targeted alpha-particle immunotherapy for acute myeloid leukemia. Am Soc Clin Oncol Educ Book. 2014:e126–31. DOI: https://doi.org/10.14694/EdBook_AM.2014. 34.e126.
41. Allen BJ, Raja C, Rizvi S, et al. Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol. Ther. 2005 Dec;4(12):1318–1324.
42. Allen BJ, Singla AA, Rizvi SMA, et al. Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma. Immunotherapy. 2011;3(9):1041–1050.
43. Allen BJ, Raja C, Rizvi S, et al. Tumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer. Phys Med Biol. 2007;52(13):L15–19.
44. Sathekge M, Knoesen O, Meckel M, et al. 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44(6):1099–100. URL: https://doi.org/10.1007/ s00259-017-3657–9.
45. Kratochwil C, Bruchertseifer F, Giesel FL, et al. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57(12):1941–1944.
46. Kratochwil C, Giesel FL, Bruchertseifer F, et al. 213Bi-DOTATOC receptor-targeted alpharadionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2106-19. DOI: 10.1007/s00259-014-2857–9.
47. Kratochwil C, Bruchertseifer F, Giesel F, et al. Ac-225-DOTATOC – an empiric dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors. J Nucl Med. 2015;56(3):1232.
48. Zalutsky MR, Reardon DA, Akabani G, et al. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med. 2008 Jan;49(1):30-8. DOI: 10.2967/jnumed.107.046938.
49. Morgenstern A, Krolicki L, Kunikowska J, et al. Targeted alpha therapy of glioblastoma multiforme: first clinical experience with 213Bi-substance P. J Nucl Med. 2014;55(Suppl. 1):390.
50. Государственный реестр лекарственных средств. [Gosudarstvennyi reestr lekarstvennykh sredstv. (In Russ).] URL: http://grls.rosminzdrav.ru/ Default.aspx.
51. A Review On The Development of Targeted Alpha Therapy in the Treatment of Cancer: Everyday Urology-Oncology Insights: Volume 2, Issue 2 https://www.urotoday.com/journal/everyday-urology-oncology-insights/ articles/98187-a-review-on-the-development-of-targeted-alpha-therapy-in-the-treatment-of-cancer-focusing-on-the-first-and-only-fda-approved-targeted-alpha-therapy-radium-223-in-the-treatment-of-metastatic-castration-resistant-prostate-cancer-mcrpc.html.
52. Резолюция по итогам Совета экспертов по определению места радия-223 в терапии пациентов с метастатическим кастрационно-резистентным раком предстательной железы. // Онкология сегодня. 2017;5(24):2–3. [Rezolyutsiya po itogam Soveta ekspertov po opredeleniyu mesta radiya-223 v terapii patsientov s metastaticheskim kastratsionno-rezistentnym rakom predstatel'noi zhelezy. Onkologiya segodnya. 2017;5(24):2–3. (In Russ.).]
53. Матвеев В.Б., Маркова А.С. Радий-223 в лечении кастрационно- резистентного рака предстательной железы с метастазами в кости. // Онкоурология. 2017;3(13):3–10. [Matveev VB, Markova AS. Radium-223 in treatment of castration-resistant prostate cancer with skeletal metastases. Cancer urology. 2017; 3(13):3–10. (In Russ).] DOI: 10.17650/1726-9776-2017-13-3-140–147.
54.
Review
For citations:
Zyryanov S.K., Zatolochina K.E. Perspective for use of the radionuclide drugs in the treatment of malignant tumors in Russiaw. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2018;(2):51-57. (In Russ.) https://doi.org/10.24411/2588-0519-2018-10044
Views:
937
Email this article 